The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology
- 31 May 2003
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (7) , 981-988
- https://doi.org/10.1016/s0959-8049(03)00065-0
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Measuring gelatinase activity in colorectal cancerEuropean Journal of Surgical Oncology, 2002
- Significance of Coexpression of Urokinase-type Plasminogen Activator, and Matrix Metalloproteinase 3 (Stromelysin) and 9 (Gelatinase B) in Colorectal CarcinomaJournal of Surgical Research, 2000
- Matrix metalloproteinases, their tissue inhibitors and colorectal cancer stagingBritish Journal of Surgery, 2000
- Membrane-type 1 matrix metalloproteinase mRNA expression in colorectal cancerDiseases of the Colon & Rectum, 2000
- Matrix metalloproteinase–1 is associated with poor prognosis in colorectal cancerNature Medicine, 1996
- Urokinase receptor and colorectal cancer survivalThe Lancet, 1994
- Matrix degrading metalloproteinasesJournal of Neuro-Oncology, 1994
- A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinasesFEBS Letters, 1992
- Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substratesAnalytical Biochemistry, 1980
- A simplified method of quantitating protein using the biuret and phenol reagentsAnalytical Biochemistry, 1978